Neural stem cell therapy for subacute and chronic ischemic stroke
Abstract Neural stem cells (NSCs) play vital roles in brain homeostasis and exhibit a broad repertoire of potentially therapeutic actions following neurovascular injury. One such injury is stroke, a worldwide leading cause of death and disability. Clinically, extensive injury from ischemic stroke re...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-06-01
|
| Series: | Stem Cell Research & Therapy |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13287-018-0913-2 |
| _version_ | 1818941060946067456 |
|---|---|
| author | Austin C. Boese Quan-Son Eric Le Dylan Pham Milton H. Hamblin Jean-Pyo Lee |
| author_facet | Austin C. Boese Quan-Son Eric Le Dylan Pham Milton H. Hamblin Jean-Pyo Lee |
| author_sort | Austin C. Boese |
| collection | DOAJ |
| description | Abstract Neural stem cells (NSCs) play vital roles in brain homeostasis and exhibit a broad repertoire of potentially therapeutic actions following neurovascular injury. One such injury is stroke, a worldwide leading cause of death and disability. Clinically, extensive injury from ischemic stroke results from ischemia-reperfusion (IR), which is accompanied by inflammation, blood-brain barrier (BBB) damage, neural cell death, and extensive tissue loss. Tissue plasminogen activator (tPA) is still the only US Food and Drug Administration–approved clot-lysing agent. Whereas the thrombolytic role of tPA within the vasculature is beneficial, the effects of tPA (in a non-thrombolytic role) within the brain parenchyma have been reported as harmful. Thus, new therapies are needed to reduce the deleterious side effects of tPA and quickly facilitate vascular repair following stroke. The Stroke Treatment Academic Industry Roundtable (STAIR) recommends that stroke therapies “focus on drugs/devices/treatments with multiple mechanisms of action and that target multiple pathways”. Thus, based on multifactorial ischemic cascades in various stroke stages, effective stroke therapies need to focus on targeting and ameliorating early IR injury as well as facilitating angiogenesis, neurogenesis, and neurorestorative mechanisms following stroke. This review will discuss the preclinical perspectives of NSC transplantation as a promising treatment for neurovascular injury and will emphasize both the subacute and chronic phase of ischemic stroke. |
| first_indexed | 2024-12-20T06:49:32Z |
| format | Article |
| id | doaj.art-736dff92e02741a68fa36e746c92b230 |
| institution | Directory Open Access Journal |
| issn | 1757-6512 |
| language | English |
| last_indexed | 2024-12-20T06:49:32Z |
| publishDate | 2018-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Stem Cell Research & Therapy |
| spelling | doaj.art-736dff92e02741a68fa36e746c92b2302022-12-21T19:49:35ZengBMCStem Cell Research & Therapy1757-65122018-06-019111710.1186/s13287-018-0913-2Neural stem cell therapy for subacute and chronic ischemic strokeAustin C. Boese0Quan-Son Eric Le1Dylan Pham2Milton H. Hamblin3Jean-Pyo Lee4Department of Physiology, Tulane University School of MedicineDepartment of Physiology, Tulane University School of MedicineDepartment of Pharmacology, Tulane University School of MedicineDepartment of Pharmacology, Tulane University School of MedicineDepartment of Physiology, Tulane University School of MedicineAbstract Neural stem cells (NSCs) play vital roles in brain homeostasis and exhibit a broad repertoire of potentially therapeutic actions following neurovascular injury. One such injury is stroke, a worldwide leading cause of death and disability. Clinically, extensive injury from ischemic stroke results from ischemia-reperfusion (IR), which is accompanied by inflammation, blood-brain barrier (BBB) damage, neural cell death, and extensive tissue loss. Tissue plasminogen activator (tPA) is still the only US Food and Drug Administration–approved clot-lysing agent. Whereas the thrombolytic role of tPA within the vasculature is beneficial, the effects of tPA (in a non-thrombolytic role) within the brain parenchyma have been reported as harmful. Thus, new therapies are needed to reduce the deleterious side effects of tPA and quickly facilitate vascular repair following stroke. The Stroke Treatment Academic Industry Roundtable (STAIR) recommends that stroke therapies “focus on drugs/devices/treatments with multiple mechanisms of action and that target multiple pathways”. Thus, based on multifactorial ischemic cascades in various stroke stages, effective stroke therapies need to focus on targeting and ameliorating early IR injury as well as facilitating angiogenesis, neurogenesis, and neurorestorative mechanisms following stroke. This review will discuss the preclinical perspectives of NSC transplantation as a promising treatment for neurovascular injury and will emphasize both the subacute and chronic phase of ischemic stroke.http://link.springer.com/article/10.1186/s13287-018-0913-2Blood-brain barrier, Neural stem cells, Stroke, Tissue plasminogen activator, Transplantation |
| spellingShingle | Austin C. Boese Quan-Son Eric Le Dylan Pham Milton H. Hamblin Jean-Pyo Lee Neural stem cell therapy for subacute and chronic ischemic stroke Stem Cell Research & Therapy Blood-brain barrier, Neural stem cells, Stroke, Tissue plasminogen activator, Transplantation |
| title | Neural stem cell therapy for subacute and chronic ischemic stroke |
| title_full | Neural stem cell therapy for subacute and chronic ischemic stroke |
| title_fullStr | Neural stem cell therapy for subacute and chronic ischemic stroke |
| title_full_unstemmed | Neural stem cell therapy for subacute and chronic ischemic stroke |
| title_short | Neural stem cell therapy for subacute and chronic ischemic stroke |
| title_sort | neural stem cell therapy for subacute and chronic ischemic stroke |
| topic | Blood-brain barrier, Neural stem cells, Stroke, Tissue plasminogen activator, Transplantation |
| url | http://link.springer.com/article/10.1186/s13287-018-0913-2 |
| work_keys_str_mv | AT austincboese neuralstemcelltherapyforsubacuteandchronicischemicstroke AT quansonericle neuralstemcelltherapyforsubacuteandchronicischemicstroke AT dylanpham neuralstemcelltherapyforsubacuteandchronicischemicstroke AT miltonhhamblin neuralstemcelltherapyforsubacuteandchronicischemicstroke AT jeanpyolee neuralstemcelltherapyforsubacuteandchronicischemicstroke |